Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech, Inc. reported second quarter 2026 revenue of $8.1 million, down from $9.3 million a year earlier, primarily due to policy effective dates shifting while onboarding a new carrier. For the first half of 2026, revenue was $16.8 million versus $17.3 million in the prior-year period.
Management emphasized “contracted revenue” and “pipeline revenue” as leading indicators. Contracted revenue for the first half totaled $32.3 million, of which $17.3 million has already been recognized, with $14.0 million expected in the second half of 2026 and $1.0 million in 2027. Pipeline revenue was $66.3 million as of July 31, with an expected conversion rate of 15%–40%, supporting reaffirmed full-year 2026 revenue guidance of $45–$50 million.
Profitability weakened as the company invested in sales, marketing and technology. Adjusted EBITDA was $(1.3) million for the quarter and $(2.6) million for the first half, compared with positive results a year ago. Net loss was $(2.5) million in Q2 and $(4.1) million for the first half. Distribution partners grew to 933, up 19.9% year over year. Health In Tech ended the quarter with $6.5 million in cash and $11.8 million in working capital, and highlighted upcoming launches such as the HitRix marketplace and its Three-Year Rate Stabilization Program.
Health In Tech, Inc., an AI-driven marketplace for self-funded health plans for small and mid-sized businesses, furnished an investor presentation outlining its business model, market opportunity and recent financial performance. The company earns primarily fee-based revenue from self-funded plan administration and carrier underwriting, while stating it has no plan or underwriting risk exposure.
The presentation reaffirms 2026 revenue guidance of $45–$50 million, versus 2025 revenue of $33.3 million, supported by $32 million of contracted revenue from first-half 2026 activity and $66 million of pipeline revenue as of July 31, 2026. For Q2 2026, revenue was $8.1 million with a gross margin of 48.7%, compared with $9.3 million and 67.7% a year earlier, and the company reported a net loss and negative Adjusted EBITDA. Cash, working capital and stockholders’ equity all increased between June 30, 2025 and June 30, 2026. The company also highlights broker and partner growth and notes risk factors that include its liquidity position and its ability to continue as a going concern.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026 while reiterating its full-year outlook. For the quarter, total revenues were $8.1 million versus $9.3 million a year earlier, and the company moved from net income of $0.6 million to a net loss of $2.5 million. Gross profit declined to $3.9 million as costs and operating expenses increased, leading to an operating loss and negative Adjusted EBITDA of $1.3 million, compared with positive $1.6 million in the prior-year quarter.
For the first half of 2026, revenues were $16.8 million compared with $17.3 million in 2025, with a net loss of $4.1 million versus net income of $1.1 million. Operating cash flow was an outflow of $6.2 million. As of June 30, 2026, the company reported $32.3 million in Contracted Revenue and cash and cash equivalents of $6.5 million; total assets rose to $29.6 million and stockholders’ equity to $19.6 million, aided by a recent PIPE financing.
As of July 31, 2026, Pipeline Revenue totaled $66.3 million, including $64.4 million in quoting or binding stages that management estimates could convert into $3.1 million to $8.3 million of GAAP revenue in 2026 and additional revenue in 2027. Supported by this contracted and pipeline activity, the company reaffirmed its 2026 GAAP revenue guidance of $45 million to $50 million and highlighted strategic initiatives such as its Three-Year Rate Stabilization Program and the planned launch of its HitRix marketplace in the second half of 2026.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026. Total revenues were $8.1 million for the quarter and $16.8 million year-to-date, slightly below the prior-year periods, while cost of revenues rose sharply, compressing margins.
For the quarter, the company recorded a net loss of $2.5 million versus net income of $0.6 million a year earlier; for the first half, it reported a net loss of $4.1 million compared with net income of $1.1 million. Operating expenses increased across sales and marketing, general and administrative, and research and development, and included a $739,773 credit loss on other receivables tied to purchased Deferred Administrative Surplus.
Cash used in operating activities was $6.2 million for the first half of 2026, compared with $2.0 million provided in the prior-year period. The company strengthened liquidity via a March 2026 PIPE financing that raised net proceeds of $6.4 million and ended June with cash and cash equivalents of $6.5 million. A program with a major stop-loss carrier led to cumulative revenue reductions of about $4.0 million and $4.0 million of interim payments, and the carrier has asserted an additional potential adjustment of up to approximately $0.4 million that remains under negotiation.
Health In Tech, Inc., an AI-enabled insurance technology platform, has filed a mixed shelf registration allowing it to offer, from time to time, up to $300,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights and units. The securities may be sold in one or more offerings with specific terms set in future prospectus supplements.
Because public float is about $23.3 million, SEC “Baby Shelf” rules currently cap primary sales under this shelf to roughly $7.8 million in any 12‑month period until float reaches $75 million. Class A common stock trades on Nasdaq as “HIT,” last reported at $1.07 per share on July 28, 2026.
Net proceeds from any offering are expected to be used for general corporate purposes, including working capital, capital expenditures, research and development and potential acquisitions. The company highlights dilution risk, potential pressure on its share price from future issuances, and limitations imposed by Baby Shelf rules. HI Card, a non-material platform, is currently paused with no 2025 revenue, with plans for a possible relaunch as a standalone service.
Health In Tech, Inc. reported that Chief Growth Officer Hasan Zain Syed surrendered 4,084 shares of Class A Common Stock on July 15, 2026 to the company to satisfy tax withholding obligations related to vesting of restricted stock. The shares were valued at $1.04 each. After this tax-withholding disposition, Syed directly holds 204,218 Class A shares, including 189,249 restricted and 14,969 unrestricted shares.
Health In Tech, Inc. reports that CEO Tim Donald Johnson had 47,217 Class A Common shares withheld at $1.04 per share to satisfy tax obligations tied to vesting restricted stock. After this tax-withholding disposition, he directly holds 23,380,692 Class A shares, including 911,932 restricted and 22,468,760 unrestricted shares; this excludes Class B shares and options.
Health In Tech, Inc. director and Chief Financial Officer Qian LinLin surrendered 28,725 Class A Common shares on July 15, 2026 to the issuer to satisfy tax withholding tied to vesting of restricted stock. After this, LinLin directly owns 9,026,575 Class A shares, including 984,340 restricted and 8,042,235 unrestricted, and also holds 2,700,000 Class B shares and 711,510 options that are excluded from this Class A total.
Shrestha Sanjay K reported acquisition or exercise transactions in this Form 4 filing.
Health In Tech, Inc. director Sanjay K. Shrestha received a grant of 18,867 restricted shares of Class A Common Stock on July 8, 2026 under the Health in Tech Equity Incentive Plan. The restricted stock vested as of the grant date, and his direct holdings increased to 101,200 shares following this award.